Related Experiment Video
Updated: Jan 16, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Immune checkpoint inhibitor-related thrombocytopenia: Current status and future perspectives
Peng-Fei Zhang1, Xiao-Cui Ye2, Xuan-Qiong Shi1
1Gastric Cancer Center, Division of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Abstract:
Immune checkpoint inhibitors (ICIs) have achieved significant success in cancer treatment, yet their associated adverse effects, particularly ICI-related thrombocytopenia (irTCP), are gaining increasing attention. IrTCP leads to serious complications, which affect treatment outcomes and quality of life. Clinical manifestations of irTCP may vary from mild to severe, necessitating careful monitoring during ICIs therapy. To date, several immune-mediated mechanisms, including the destruction of platelets and bone marrow suppression, have been revealed to play crucial roles in the pathogenesis of irTCP. Despite advancements in understanding these mechanisms, challenges remain in the timely diagnosis and effective management of irTCP. In this review, we synthesize the latest findings in the field and elucidate the mechanisms, clinical manifestations, diagnostic approaches, and management strategies of irTCP, aiming to provide insights for clinical practice and future research directions.
Related Concept Videos
Tumor Immunotherapy
Venous Thrombosis III: Interprofessional Care
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Therapeutic Drug Monitoring: Overview and Classification
Inhibition of Cdk Activity

